| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3781 |
| Trial ID | NCT06287528 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | 19-28z/IL-18 CAR T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) |
| Year | 2024 |
| Country | United States |
| Company sponsor | Memorial Sloan Kettering Cancer Center |
| Other ID(s) | 23-307 |
| Cohort1: without lymphodepleting chemotherapy | |||||||||||
|
|||||||||||
| Cohort2: with lymphodepleting chemotherapy | |||||||||||
|
|||||||||||